JPWO2021138600A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021138600A5 JPWO2021138600A5 JP2022565737A JP2022565737A JPWO2021138600A5 JP WO2021138600 A5 JPWO2021138600 A5 JP WO2021138600A5 JP 2022565737 A JP2022565737 A JP 2022565737A JP 2022565737 A JP2022565737 A JP 2022565737A JP WO2021138600 A5 JPWO2021138600 A5 JP WO2021138600A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- binding domain
- nanoparticle
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962956033P | 2019-12-31 | 2019-12-31 | |
| US62/956,033 | 2019-12-31 | ||
| PCT/US2020/067729 WO2021138600A1 (en) | 2019-12-31 | 2020-12-31 | Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508616A JP2023508616A (ja) | 2023-03-02 |
| JP2023508616A5 JP2023508616A5 (https=) | 2024-01-12 |
| JPWO2021138600A5 true JPWO2021138600A5 (https=) | 2024-01-12 |
Family
ID=76685916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565737A Pending JP2023508616A (ja) | 2019-12-31 | 2020-12-31 | 治療部位での免疫系応答性を刺激し維持するためのナノ粒子システム |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230331804A1 (https=) |
| EP (1) | EP4085137A4 (https=) |
| JP (1) | JP2023508616A (https=) |
| KR (1) | KR20220130712A (https=) |
| CN (1) | CN115135764A (https=) |
| AU (1) | AU2020417305A1 (https=) |
| BR (1) | BR112022013068A2 (https=) |
| CA (1) | CA3162629A1 (https=) |
| IL (1) | IL294441A (https=) |
| MX (1) | MX2022008183A (https=) |
| WO (1) | WO2021138600A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111629715A (zh) | 2018-01-18 | 2020-09-04 | 弗莱德哈钦森癌症研究中心 | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023081644A1 (en) * | 2021-11-02 | 2023-05-11 | Engage Biologics Inc. | Materials and methods for treatment with mrna encoding multispecific binding molecules |
| EP4561537A2 (en) * | 2022-07-27 | 2025-06-04 | Trustees Of Tufts College | Lipid nanoparticles for immunotherapy |
| CN116003627B (zh) * | 2022-09-16 | 2025-05-13 | 四川大学华西医院 | NKG2D-NKp46细胞接合器分子及其用途 |
| CN116874600B (zh) * | 2023-07-13 | 2024-07-05 | 浙江大学 | 来自纳米抗体可靶向cd163受体的短肽的制备方法及其应用 |
| WO2025026553A1 (en) * | 2023-08-02 | 2025-02-06 | BioNTech SE | Agents and methods for targeted delivery to cells |
| WO2025128615A1 (en) * | 2023-12-12 | 2025-06-19 | Seagen Inc. | Multispecific egfr antibodies and use in the treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2294579C (en) * | 1997-06-23 | 2007-10-09 | Sequus Pharmaceuticals, Inc. | Liposome-entrapped polynucleotide composition and method |
| WO1999064074A1 (en) * | 1998-06-11 | 1999-12-16 | The Trustees Of The University Of Pennsylvania | Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| CN119564879A (zh) * | 2015-08-18 | 2025-03-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| AU2016308286B2 (en) * | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| EP3353309A4 (en) * | 2015-09-25 | 2019-04-10 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHOD FOR GENERIC EDITING |
| AU2017313806B2 (en) * | 2016-08-17 | 2023-07-20 | Orbis Health Solutions Llc | Tumor-targeting bead vectors and methods of using the same |
| CN111629715A (zh) * | 2018-01-18 | 2020-09-04 | 弗莱德哈钦森癌症研究中心 | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 |
| CR20200459A (es) * | 2018-04-13 | 2020-11-11 | Hoffmann La Roche | Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl |
| JP2021523110A (ja) * | 2018-05-01 | 2021-09-02 | フレッド ハッチンソン キャンサー リサーチ センター | 遺伝子発現のためのナノ粒子及びその使用 |
-
2020
- 2020-12-31 CN CN202080091519.9A patent/CN115135764A/zh active Pending
- 2020-12-31 KR KR1020227026301A patent/KR20220130712A/ko active Pending
- 2020-12-31 BR BR112022013068A patent/BR112022013068A2/pt unknown
- 2020-12-31 CA CA3162629A patent/CA3162629A1/en active Pending
- 2020-12-31 WO PCT/US2020/067729 patent/WO2021138600A1/en not_active Ceased
- 2020-12-31 JP JP2022565737A patent/JP2023508616A/ja active Pending
- 2020-12-31 IL IL294441A patent/IL294441A/en unknown
- 2020-12-31 MX MX2022008183A patent/MX2022008183A/es unknown
- 2020-12-31 AU AU2020417305A patent/AU2020417305A1/en active Pending
- 2020-12-31 EP EP20911288.7A patent/EP4085137A4/en active Pending
- 2020-12-31 US US17/758,296 patent/US20230331804A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Makuku et al. | Current and future perspectives of PD‐1/PDL‐1 blockade in cancer immunotherapy | |
| Ovais et al. | Tailoring nanomaterials for targeting tumor‐associated macrophages | |
| JPWO2021138600A5 (https=) | ||
| US9574210B2 (en) | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof | |
| Zhao et al. | Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy | |
| Moosavian et al. | 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells | |
| Liu et al. | Powerful anticolon tumor effect of targeted gene immunotherapy using folate-modified nanoparticle delivery of CCL19 to activate the immune system | |
| Muralidharan et al. | Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration | |
| Feng et al. | Targeting dual gene delivery nanoparticles overcomes immune checkpoint blockade induced adaptive resistance and regulates tumor microenvironment for improved tumor immunotherapy | |
| Chen et al. | Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects | |
| Li et al. | Bioinspired magnetic nanocomplexes amplifying STING activation of tumor-associated macrophages to potentiate cancer immunotherapy | |
| Wang et al. | Nanotechnology‐based CAR‐T strategies for improving efficacy and safety of tumor immunotherapy | |
| Bottai et al. | Progress in nonviral gene therapy for breast cancer and what comes next? | |
| Mizrahy et al. | Advanced strategies in immune modulation of cancer using lipid-based nanoparticles | |
| Dhas et al. | Nanoengineered platform-based microenvironment-triggered immunotherapy in cancer treatment | |
| Fernandes et al. | Emerging strategies for immunotherapy of solid tumors using lipid‐based nanoparticles | |
| Liao et al. | Regulation of cancer-associated fibroblasts for enhanced cancer immunotherapy using advanced functional nanomedicines: an updated review | |
| JP2020535119A5 (https=) | ||
| Gu et al. | A bioactive nanocomposite integrated specific TAMs target and synergistic TAMs repolarization for effective cancer immunotherapy | |
| WO2021016106A8 (en) | Multilamellar rna nanoparticles | |
| Huang et al. | Tuning surface valences of nanoengagers to enhance their structural advantages for efficiently redirecting T cells against solid tumors | |
| Chen et al. | Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunity | |
| Santerre et al. | Biomaterials’ enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment | |
| Wu et al. | Targeting the undruggable: advances and obstacles in current RNAi therapy | |
| Liu et al. | Polyoxazoline‐Based Gene Delivery System Mediated Tumor Vascular Normalization and Extracellular Matrix Degradation to Inhibit Cancer Growth, Recurrence, and Metastasis |